Armani R G, Ramezani A, Yasir A, Sharama S, Canziani M E F, Raj D S
Nephrology Division, Department of Medicine, Federal University of São Paulo, São Paulo, Brazil.
Division of Renal Diseases and Hypertension, The George Washington University School of Medicine, 2150 Pennsylvania Avenue NW, Washington, DC, 20037, USA.
Curr Hypertens Rep. 2017 Apr;19(4):29. doi: 10.1007/s11906-017-0727-0.
With over 100 trillion microbial cells, the gut microbiome plays important roles in both the maintenance of health and the pathogenesis of disease. Gut microbiome dysbiosis, resulted from alteration of composition and function of the gut microbiome and disruption of gut barrier function, is commonly seen in patients with chronic kidney disease (CKD). The dysbiotic gut microbiome generates excessive amounts of uremic toxins, and the impaired intestinal barrier permits translocation of these toxins into the systemic circulation. Many of these uremic toxins have been implicated in the progression of CKD and increased cardiovascular risk. Various therapeutic interventions have been proposed that aim to restore gut microbiome symbiosis. If proven effective, these interventions will have a significant impact on the management of CKD patients. In this review, we discuss the consequences of gut microbiome dysbiosis in the context of CKD, discuss the consequences of gut dysbiosis, and highlight some of the recent interventions targeting the gut microbiome for therapeutic purposes.
肠道微生物群含有超过100万亿个微生物细胞，在维持健康和疾病发病机制中都发挥着重要作用。肠道微生物群失调是慢性肾脏病（CKD）患者常见的情况，它是由肠道微生物群的组成和功能改变以及肠道屏障功能破坏引起的。失调的肠道微生物群会产生过量的尿毒症毒素，而受损的肠道屏障会使这些毒素进入体循环。许多这些尿毒症毒素与CKD的进展和心血管风险增加有关。已经提出了各种旨在恢复肠道微生物群共生的治疗干预措施。如果被证明有效，这些干预措施将对CKD患者的管理产生重大影响。在这篇综述中，我们讨论了在CKD背景下肠道微生物群失调的后果，讨论了肠道失调的后果，并重点介绍了一些最近针对肠道微生物群的治疗性干预措施。
